Physician profile
Heather N Kinsel-Evans
NPI 1588697890
$1,207.74
in general payments reported to CMS, 2019-2025
23 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $249 · 2023: $389 · 2024: $232 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $169.58 | 2022-2025 | Wegovy |
| Amgen INC. | $145.93 | 2023-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $143.14 | 2022-2025 | |
| Lilly USA, LLC | $126.09 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $122.89 | 2022-2025 | Airsupra, Farxiga, Flumist Quadrivalent |
| Pfizer INC. | $55.83 | 2022-2025 | |
| Glaxosmithkline, LLC. | $45.41 | 2023-2024 | Shingrix, Bexsero, Arexvy |
| Sanofi Pasteur INC. | $38.11 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.14 | 2022-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $35.14 | 2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $32.65 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $30.82 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $26.40 | 2022 | |
| Abbott Laboratories | $24.08 | 2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.65 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $23.59 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $21.20 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $19.50 | 2025 | Voquezna |
| Seqirus USA INC | $18.80 | 2022 | |
| Grifols USA, LLC | $18.00 | 2023 | Prolastin-C Liquid |
| Astellas Pharma US INC | $17.62 | 2024 | Veozah |
| Exact Sciences Corporation | $17.52 | 2023 | Cologuard Collection Kit |
| Cequr Corporation | $14.65 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Kinsel-Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.